Current Practices in Ocular Toxoplasmosis: A Survey of Brazilian Uveitis Specialists

REFERENCES

• Furtado JM, Winthrop KL, Butler NJ, et al. Ocular toxoplasmosis I: parasitology, epidemiology and public health. Clin Experiment Ophthalmol. 2013;41:82–94.
   PubMed Web of Science ®Google Scholar
• Commodaro AG, Belfort RN, Rizzo LV, et al. Ocular toxoplasmosis: an update and review of the literature. Mem Inst Oswaldo Cruz. 2009;104:345–350.
   PubMed Web of Science ®Google Scholar
• GN Holland. Ocular toxoplasmosis: a global reassessment. Am J Ophthalmol. 2003;136:973–988.
   PubMed Web of Science ®Google Scholar
• Dubey JP, Lago EG, Gennari SM, et al. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology. 2012;139:1375–1424.
   PubMed Web of Science ®Google Scholar
• Glasner PD, Silveira C, Kruszon-Moran D, et al. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol. 1992;114:136–144.
   PubMed Web of Science ®Google Scholar
• Jones JL, Kruszon-Moran D, Sanders-Lewis K, et al. Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade. Am J Trop Med Hyg. 2007;77:405–410.
   PubMed Web of Science ®Google Scholar
• GN Holland. Ocular toxoplasmosis: a global reassessment. Am J Ophthalmol. 2004;137:1–17.
   PubMed Web of Science ®Google Scholar
• GN Holland, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:102–114.
   PubMed Web of Science ®Google Scholar
• Lum F, JL Jones, GN Holland, et al. Survey of ophthalmologists about ocular toxoplasmosis. Am J Ophthalmol. 2005;140:724–726.
   PubMed Web of Science ®Google Scholar
• RE Engstrom, GN Holland, RB Nussenblatt, et al. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 1991;111:601–610.
   PubMed Web of Science ®Google Scholar
• Torun N, Sherif Z, Garweg J, et al. [Diagnosis and treatment of ocular toxoplasmosis: a survey of German-speaking ophthalmologists]. Ophthalmologe. 2008;105:1023–1028.
   PubMed Web of Science ®Google Scholar
• Basu S, Biswas J, Pleyer U, et al. An ophthalmologist survey-based study of the atypical presentations and current treatment practices of ocular toxoplasmosis in India. J Parasit Dis. 2011;35:148–154.
   PubMedGoogle Scholar
• Fernandes L, Oréfice F. Aspectos clínicos e epidemiológicos das uveítes, em serviços de referência em Belo Horizonte, de 1970 a 1993: parte II. Rev Bras Oftalmol. 1996;55:579–592.
   Google Scholar
• Gouveia EB, Yamamoto JH, Abdalla M, et al. Causas das uveítes em serviço terciário em São Paulo, Brasil. Arq Bras Oftalmol. 2004;67:139–145.
   Google Scholar
• Wakefield D, Cunningham ET, Pavesio C, et al. Controversies in ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19:2–9.
   PubMed Web of Science ®Google Scholar
• Khan A, Jordan C, Muccioli C, et al. Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis, Brazil. Emerg Infect Dis. 2006;12:942–949.
   PubMed Web of Science ®Google Scholar
• Bosch-Driessen EH, Rothova A. Sense and nonsense of corticosteroid administration in the treatment of ocular toxoplasmosis. Br J Ophthalmol. 1998;82:858–860.
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Davidian M, Rainey PM, et al. Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. Antimicrob Agents Chemother. 1996;40:1360–1365.
   PubMed Web of Science ®Google Scholar
• Kaufman HE, Caldwell LA. Pharmacological studies of pyrimethamine (Daraprim) in man. AMA Arch Ophthalmol. 1959;61:885–890.
   PubMedGoogle Scholar
• Sabates R, Pruett RC, Brockhurst RJ. Fulminant ocular toxoplasmosis. Am J Ophthalmol. 1981;92:497–503.
   PubMed Web of Science ®Google Scholar
• Nozik RA. Results of treatment of ocular toxoplasmosis with injectable corticosteroids. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83:811–818.
   PubMedGoogle Scholar
• O’Connor GR. Dangers of steroid treatment in toxoplasmosis. Arch Ophthalmol. 1976;94:213.
   PubMed Web of Science ®Google Scholar
• Stanford MR, See SE, Jones LV, et al. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review. Ophthalmology. 2003;110:926–931.
   PubMed Web of Science ®Google Scholar
• de-la-Torre A, Stanford M, Curi A, et al. Therapy for ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19:314–320.
   PubMed Web of Science ®Google Scholar
• Grossman PL, Remington JS. The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo. Am J Trop Med Hyg. 1979;28:445–455.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Sadoughi M-M, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;112:1876–1882.
   Google Scholar
• Garweg JG, Stanford MR. Therapy for ocular toxoplasmosis – the future. Ocul Immunol Inflamm. 2013;21:300–305.
   PubMed Web of Science ®Google Scholar
• Holland GN. Prospective, randomized trial of trimethoprim/sulfamethoxazole vs. pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis: discussion. Ophthalmology. 2005;112:1882–1884.
   PubMed Web of Science ®Google Scholar
• Rothova A, Meenken C, Buitenhuis HJ, et al. Therapy for ocular toxoplasmosis. Am J Ophthalmol. 1993;115:517–523.
   PubMed Web of Science ®Google Scholar
• Laccheri B, Fiore T, Papadaki T, et al. Adverse drug reactions to treatments for ocular toxoplasmosis: a retrospective chart review. Clin Ther. 2008;30:2069–2074.
   PubMed Web of Science ®Google Scholar
• Zamora YF, Arantes TEFE, Reis FA, et al. Local treatment of toxoplasmic retinochoroiditis with intravitreal clindamycin and dexamethasone. Arq Bras Oftalmol. 2015;78:216–219.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118:134–141.
   PubMed Web of Science ®Google Scholar
• Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol. 2013;33:39–46.
   PubMed Web of Science ®Google Scholar
• Sobrin L, Kump LI, Foster CS. Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina (Philadelphia, Pa). 2007;27:952–957.
   PubMed Web of Science ®Google Scholar
• Silveira C, Belfort R, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134:41–46.
   PubMed Web of Science ®Google Scholar
• Felix JPF, Lira RPC, Zacchia RS, et al. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. Am J Ophthalmol. 2014;157:762–766.
   PubMed Web of Science ®Google Scholar
• Silveira C, Muccioli C, Nussenblatt R, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis: 10 years of follow-up. Ocul Immunol Inflamm. 2015;23:246–247.
   PubMed Web of Science ®Google Scholar